STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more

Novartis acquired Myricx Bio for $1.1 billion to advance its antibody-drug conjugate (ADC) pipeline with a novel NMTi payload. Congressional Republicans passed a bill funding the FDA, including a report urging the agency to implement requirements for diversifying clinical trials.